Intech Investment Management LLC Reduces Position in Danaher Co. (NYSE:DHR)

Intech Investment Management LLC reduced its stake in shares of Danaher Co. (NYSE:DHR) by 29.4% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 11,049 shares of the conglomerate’s stock after selling 4,608 shares during the period. Intech Investment Management LLC’s holdings in Danaher were worth $2,761,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Cape Investment Advisory Inc. acquired a new stake in shares of Danaher in the 4th quarter worth $25,000. Tsfg LLC lifted its stake in Danaher by 733.3% during the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after purchasing an additional 88 shares in the last quarter. CarsonAllaria Wealth Management Ltd. purchased a new position in shares of Danaher during the second quarter worth $25,000. nVerses Capital LLC acquired a new stake in shares of Danaher in the second quarter valued at $25,000. Finally, Redmont Wealth Advisors LLC acquired a new position in Danaher during the 1st quarter worth about $30,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, SVP Brian W. Ellis sold 9,600 shares of the stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the transaction, the senior vice president now owns 20,230 shares in the company, valued at approximately $5,566,486.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at $5,566,486.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Rainer Blair sold 9,007 shares of Danaher stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the sale, the chief executive officer now owns 97,983 shares of the company’s stock, valued at $27,435,240. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 39,659 shares of company stock worth $11,042,433. Corporate insiders own 11.10% of the company’s stock.

Danaher Stock Down 1.4 %

Shares of NYSE:DHR opened at $272.63 on Monday. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $281.70. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. The firm’s 50-day simple moving average is $267.62 and its 200-day simple moving average is $257.19. The company has a market cap of $201.93 billion, a price-to-earnings ratio of 46.21, a PEG ratio of 4.48 and a beta of 0.83.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. The company had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm’s revenue for the quarter was down 2.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.05 EPS. As a group, equities research analysts predict that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be issued a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.40%. The ex-dividend date is Friday, September 27th. Danaher’s dividend payout ratio (DPR) is currently 18.31%.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on DHR shares. Wells Fargo & Company initiated coverage on Danaher in a research report on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 target price for the company. Stifel Nicolaus raised their price target on shares of Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a research report on Wednesday, July 24th. Evercore ISI reduced their price objective on Danaher from $266.00 to $260.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 2nd. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. Finally, Robert W. Baird boosted their price objective on Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. Seven analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $278.94.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.